Cindy Lampner

Tocilizumab was associated with significant improvements in hemoglobin and hematocrit over 2 years of treatment in patients with rheumatoid arthritis.

Chondroitin sulfate was superior to placebo and proved equivalent to celecoxib for osteoarthritis of the knee.

Use of the JAK inhibitor peficitinib in combination with certain csDMARDs results in a dose-dependent ACR20 response rate in patients with RA over 12 weeks.

No clear association was found between health status and ultrasound remission in patients with rheumatoid arthritis in clinical remission.

Patients with RA who were treated in the first 6 months had a lower risk of death.

The first evidence-based recommendations on the use of imaging in osteoarthritis clinical practice have been released by the European League Against Rheumatism.

Patients with Alzheimer disease who were receiving benzodiazepines had a risk for pneumonia 30% greater than that of matched control patients.

High-risk patients who did not receive guidelines-recommended prophylactic hydration prior to procedures requiring iodinated contrast media had the same rate of contrast-induced nephropathy as patients who received usual care.

An abbreviated version of the Pain Medication Attitudes Questionnaire (PMAQ-14) has been developed and tested.

Buprenorphine/naloxone treatment initiated in the emergency department and prolonged for 10 weeks in primary care improved treatment engagement and reduced opioid use compared with referral or brief intervention.